
20

25

30



wherein X is CR7; N; or N\*O';

wherein Y is O; CO; Sty CR3R5; or NR6;

wherein each  $R_2$  is independently H; F; Cl; Br; I;  $-NO_2$ , -CN; straight chained of branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy; -OH;  $-(CH_2)_4OH$ ;  $-COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benxyl;

wherein each  $R_3$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_2$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; -( $CH_2$ )<sub>q</sub>OH; -OH; =N-OR<sub>4</sub>;  $CO_2$ R<sub>4</sub>;  $CO_2$ R<sub>4</sub>;  $CO_3$ R<sub>4</sub>; phenyl; or benzyl;

wherein each  $R_4$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; or phenyl;

Bot

10

15

wherein each  $R_5$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluoroalkyl, or  $C_1$ - $C_4$  polyfluoroalkyl;

wherein  $R_6$  is H; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_2$ - $C_4$  alkoxy; - $CH_2CH_2(CH_2)_qOH$ ;  $COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

wherein each  $R_7$  is independently H; -CN; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; -OH; -( $CH_2$ )<sub>q</sub>OH; - $COR_4$ ;  $CO_2R_4$ ; CONHR<sub>4</sub>; phenyl; or benzyl;

wherein m and n are each independently 0, 1, 2 or 3, provided that m+n is 2 or 3;

wherein each p is independently 0,\1 or 2; and

wherein each q is independently 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

25

wherein each of Z1, Z2 and Z3 is N or  $CR_2$ , with the proviso that either one of Z1, Z2 or Z3 is N and the others of Z1, Z2 or Z3 are  $CR_2$ , or both Z1 and Z3 are N and Z2 is  $CR_2$ ;

15

wherein  $R_1$  is H; F; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy, -OH; or -( $CH_2$ ) oOH;

20

wherein each  $R_2$  is independently H; F; C1; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_2$ - $C_4$  alkoxy; -OH; -(CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>;  $CO_2R_4$ ; CONHR<sub>4</sub>; phenyl; or benzyl;

25

wherein each  $R_4$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; or phenyl; and

30

wherein q is each independently 0,  $\frac{1}{2}$ , 2 or 3;

or a pharmaceutically acceptable salt \thereof.

Sul	3.	The compound of claim 1 or 2, wherein the compound comprises the (+) enantiomer.
<b>K</b> 5	4.	The compound of claim 1 or 2, wherein the compound comprises the (-) enantiomer.
	5.	The compound of claim 1, wherein Y is $CR_3R_5$ , and m+n is 3.
10	6.	The compound of claim 1 wherein Y is $CR_3R_5$ and m+n is 2.
4==	7.	The compound of claim 1, wherein Y is $NR_6$ .
15 15	8.	The compound of claim 1, wherein X is N.
	9.	The compound of claim $\Omega$ , wherein two of Z1, Z2 and Z3 are $CR_2$ and the other is $N$ .
	10.	The compound of claim 5, wherein p is at least 1 and at least one $R_3$ is methyl.
	11.	The compound of claim 5, wherein at least one $R_{\bar{z}}$ is methyl.
<b>25</b>	12.	The compound of claim 6, wherein at least one $R_2$ is bromo
30	13.	The compound of any one of claims 10, 11, or 12, wherein $X$ is $N$ .
50B A4	14.	The compound of claim 9, wherein at least one $R_2$ is methyl or phenyl.

16. The compound of claim 6 having the structure:

5

10

15

17. The compound of claim of plaving the structure:

20

TODEROL BOYENDE

25

10

The compound of claim 12 having the structure: 19.


15

20

nggrane obecut

The compound of claim 15 having the structure: 20.

25



25

30

35

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 2 and a pharmaceutically acceptable carrier.

22. A method for treating an  $\alpha_2$  adrenergic receptor associated disorder in a subject, which comprises administering to the subject an amount of a compound effective to treat the disorder, wherein the compound has the structure:

 $\begin{pmatrix} R_3 \\ R_3 \\ R_3 \end{pmatrix}_p \begin{pmatrix} R_2 \\ N \\ N \end{pmatrix}_{R_2} \begin{pmatrix} H \\ N \\ N \end{pmatrix}_{R_3} \begin{pmatrix} H \\ N \\ N \end{pmatrix}_{R_3}$ 

wherein X is CR<sub>7</sub>; N; or N<sup>+</sup>O<sup>-</sup>;


wherein Y is O; CO; S;  $\C R_3 R_5$ ; or  $NR_6$ ;

wherein each  $R_2$  is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; -OH; -(CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>;  $CO_2R_4$ ; CONHR<sub>4</sub>; phenyl; or benzyl;

wherein each  $R_3$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; -( $CH_2$ )<sub>q</sub>OH; -OH; =N-OR<sub>4</sub>;  $COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

		wherein each $R_4$ is independently $H$ ; straight chained or branched $C_1$ - $C_4$ alkyl, $C_1$ - $C_4$ monofluoroalkyl or $C_1$ - $C_4$ polyfluoroalkyl; or phenyl;
Subj	5	wherein each $R_5$ is independently H; straight chained or branched $C_1$ - $C_4$ alkyl, $C_1$ - $C_4$ monofluoroalkyl, or $C_1$ - $C_4$ polyfluoroalkyl;
	10	wherein $R_6$ is H; straight chained or branched $C_1$ - $C_4$ alkyl; $C_1$ - $C_4$ monofluoroalkyl or $C_1$ - $C_4$ polyfluoroalkyl; straight chained or branched $C_1$ - $C_4$ alkoxy; - $CH_2CH_2(CH_2)_qOH$ ; $COR_4$ ; $CO_2R_4$ ; $CONHR_4$ ; phenyl; or benzyl;
	15	wherein each $R_7$ is independently $H$ ; -CN; straight chained or branched $C_1$ - $C_4$ alkyl; $C_1$ - $C_4$ monofluoroalkyl or $C_1$ - $C_4$ polyfluoroalkyl; straight chained or branched $C_1$ - $C_4$ alkoxy; -OH; -(CH <sub>2</sub> ) $_3$ OH; -COR $_4$ ; CO $_2$ R $_4$ ; CONHR $_4$ ; phenyl; or benzyl;
	20 .	wherein m and n are each independently 0, 1, 2 or 3, provided that m+n is 2 or 3; wherein each p is independently 0, 1 or 2; and
<u>.</u>	25	wherein each q is independently 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof

23. A method for treating an  $\alpha_{\text{s}}$  adrenergic receptor associated disorder in a subject, which comprises administering to the subject an amount of a compound effective to treat the disorder, wherein the compound has the structure:



15

10

5

wherein each of Z1, Z2 and Z3 is N or  $CR_2$ , with the proviso that either one of Z1, Z2 or Z3 is N and the others of Z1, Z2 or Z3 are  $CR_2$ , or both Z1 and Z3 are N and Z2 is  $CR_2$ ;

20

wherein  $R_1$  is H; F; straight chained or branched  $C_1-C_4$  alkyl,  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy, -OH; or -( $CH_2$ )<sub>q</sub>OH;

25

wherein each  $R_2$  is independently H; F; Cl; Br; I;  $-NO_2$ , -CN; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; -OH;  $-(CH_2)_3OH$ ;  $-COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

30

wherein each  $R_4$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluorealkyl or  $C_1$ - $C_4$  polyfluorealkyl; or phenyl; and

wherein q is each independently 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

Sub pþ

5

The method of claim 22 or 23, wherein the disorder is 24. migraine headache, hyperbension or glaucoma.

10

25

A method for treating pain in a subject, comprises administering to the subject an amount of a compound effective to treat the subject's pain, wherein the compound has the structure:

DOOKTIOS CENTO

15

20

wherein X is CR7; N; or N+O;

25

wherein Y is O; CO; S; CR; R5; or NR5;

30

wherein each  $R_2$  is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched C1-C4 alkyl; C1-C4 monofluoroalkyl or  $C_1$ - $C_4$  polykluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; OH; - $(CH_2)_3OH$ ; - $COR_4$ ; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

wherein each R; is independently H; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluordalkyl or  $C_1-C_4$ polyfluoroalkyl; straight chained or branched C1-C4

		alkoxy; $-(CH_2)_qOH$ ; $-OH$ ; $=N-OR_4$ ; $COR_4$ ; $CO_2R_4$ ; $CONHR_4$ ; phenyl; or benzyl;
. 10	5	wherein each $R_4$ is independently H; straight chained or branched $C_1$ - $C_4$ alkyl, $C_1$ - $C_4$ monofluoroalkyl or $C_1$ - $C_4$ polyfluoroalkyl; or phenyl;
		wherein each R <sub>5</sub> is independently H; straight chained or
		branched C <sub>1</sub> -C <sub>4</sub> alkyl, C <sub>1</sub> -C <sub>4</sub> monofluoroalkyl, or C <sub>1</sub> -C <sub>4</sub>
	10	polyfluoroalkyl;
SUV		wherein $R_6$ is $H$ ; straight chained or branched $C_1$ - $C_2$
$C^{\prime}$		alkyl; C <sub>1</sub> -C <sub>4</sub> monofluoroalkyl or C <sub>1</sub> -C <sub>4</sub> polyfluoroalkyl;
i)		straight chained or branched C <sub>1</sub> -C <sub>4</sub> alkoxy; -
o O	15	CH <sub>2</sub> CH <sub>2</sub> (CH <sub>2</sub> ) <sub>q</sub> OH; COR <sub>4</sub> ; CO <sub>2</sub> R <sub>4</sub> ; CONHR <sub>4</sub> ; phenyl; or benzyl;
		wherein each $R_7$ is independently H; -CN; straight
		chained or branched $\mathcal{O}_1$ -C, alkyl; $C_1$ -C, monofluoroalkyl
		or $C_1$ - $C_4$ polyfluoroalky ; straight chained or branched
I. Call Last the case of the c	20	$C_1-C_4$ alkoxy; -OH; -( $C_{12}$ ) <sub>4</sub> OH; -COR <sub>4</sub> ; $CO_2R_4$ ; CONHR <sub>4</sub> ;
		phenyl; or benzyl;
		wherein m and n are each independently 0, 1, 2 or 3,
		provided that m+n is 2 or 3;
	25	provided chae min is 2 or 3,
	23	wherein each p is independently 0, 1 or 2; and
		wherein each q is independently 0 1, 2 or 3;
	30	or a pharmaceutically acceptable salt thereof.


V

comprises administering to the subject an amount of a

in a

subject,

which



A method for treating pain

26.

5

10

15

20

25

30

35

wherein each of Z1, Z2 and Z3 is N or  $CR_2$ , with the proviso that either one of Z1, Z2 or Z3 is N and the others of Z1, Z2 or Z3 are  $CR_2$ , or both Z1 and Z3 are N and Z2 is  $CR_2$ ;

wherein  $R_1$  is H; F; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy, -OH; or -(CH<sub>2</sub>)<sub>q</sub>OH;

wherein each  $R_2$  is independently H; F; Cl; Br; I;  $-NO_2$ , -CN; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight chained or branched  $C_1$ - $C_4$  alkoxy; -OH;  $-(CH_2)_9OH$ ;  $-COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

wherein each  $R_4$  is independently H; straight chained or branched  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; or phenyl; and

wherein q is each independently 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof

actor B<sup>2</sup>